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Abstract
Background: Current gene- and cell-based therapies have significant limitations which impede widespread clinical
application. Taking diabetes mellitus as a paradigm, we have sought to overcome these limitations by ex vivo electrotransfer
of a nonviral insulin expression vector into primary hepatocytes followed by immediate autologous reimplantation in a
preclinical model of diabetes.
Methods and Results: In a single 3-hour procedure, hepatocytes were isolated from a surgically resected liver wedge,
electroporated with an insulin expression plasmid ex vivo and reimplanted intraparenchymally under ultrasonic guidance
into the liver in each of 10 streptozotocin-induced diabetic Yorkshire pigs. The vector was comprised of a bifunctional,
glucose-responsive promoter linked to human insulin cDNA. Ambient glucose concentrations appropriately altered human
insulin mRNA expression and C-peptide secretion within minutes in vitro and in vivo. Treated swine showed correction of
hyperglycemia, glucose intolerance, dyslipidemia and other metabolic abnormalities for $47 weeks. Metabolic correction
correlated significantly with the number of hepatocytes implanted. Importantly, we observed no hypoglycemia even under
fasting conditions. Direct intrahepatic implantation of hepatocytes did not alter biochemical indices of liver function or
induce abnormal hepatic lobular architecture. About 70% of implanted hepatocytes functionally engrafted, appeared
histologically normal, retained vector DNA and expressed human insulin for $47 weeks. Based on structural tissue analyses
and transcriptome data, we showed that early correction of diabetes attenuated and even prevented pathological changes
in the eye, kidney, liver and aorta.
Conclusions: We demonstrate that autologous hepatocytes can be efficiently, simply and safely modified by
electroporation of a nonviral vector to express, process and secrete insulin durably. This strategy, which achieved
significant and sustained therapeutic efficacy in a large preclinical model without adverse effects, warrants consideration for
clinical development especially as it could have broader future applications for the treatment of other acquired and
inherited diseases for which systemic reconstitution of a specific protein deficiency is critical.
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Introduction
Consistent demonstration that hepatocyte transplantation could
correct metabolic abnormalities in experimental animals [1–4] led
naturally to clinical attempts to treat metabolic disorders about
10 years ago [5]. As of 2006, 21 patients worldwide had received
hepatocyte transplantation for liver-directed metabolic disorders
with, however, only modest success [6]. Several reasons may
explain the incommensurate clinical outcomes of hepatocyte
transplantation in human subjects compared to murine models.
Metabolic correction in experimental animals is greatly favored
under conditions of therapeutic liver repopulation (i.e. when donor
hepatocytes have a natural or iatrogenic proliferative advantage
over hepatocytes of the recipient host) [7]. However, such
conditions rarely occur naturally in humans and, if induced, carry
unacceptable clinical risks. Nearly all hepatocyte transplantations
have used allogeneic donors. Despite allografts from living-related
donors and attempts at optimizing immunosuppresion regimens
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1734[8,9], allograft rejection is another reason for the limited success of
hepatocyte transplantation to date. Although conventional gene
therapy methods of in vivo vector administration appear to
overcome these difficulties, they present other problems. These are
the general inability to limit viral vector delivery only to specific
cell types and the known risks of immunogenic and genotoxic
adverse effects. Moreover, transduced cells that express viral
proteins are targets for host immunological destruction–a cause of
transient transgene expression [10].
Unlike inborn errors of metabolism in which the liver is the
primary disease organ, other inherited and acquired disorders
caused by lack of specific proteins e.g. diabetes mellitus and the
hemophilias, could benefit more readily from hepatocyte trans-
plantation since liver repopulation is not required to correct these
diseases. Moreover, as the liver is structurally and functionally
normal, therapeutic autologous hepatocyte transplantation could
be feasible. Combining autologous rather than allogeneic
hepatocytes with ex vivo gene transfer has several advantages.
Hepatocytes from well-planned liver resections are likely to be of
higher quality, can be used fresh rather than cryopreserved and
allow the use of effective techniques for transfecting primary
somatic cells e.g. ex vivo high voltage electroporation that would
cause tissue necrosis in vivo. Autologous cells also overcome the
problem of donor scarcity and do not subject patients to chronic
immunosuppression.
We have chosen insulin-deficient diabetes mellitus as a clinically
relevant model to investigate the ability of autologous adult
hepatocytes to reconstitute normal metabolism in a large animal
model. Although many studies have shown amelioration and even
cure of murine diabetes [11–15], durable correction has not yet
been reported using autologous cells in a preclinical model,
indicating that current techniques are not easily scalable for
clinical application. Hepatocytes are proficient in protein synthesis
and secretion, and are physiologically glucose-sensing cells capable
of glucose-stimulated transcription [16]. Unlike pancreatic b cells
with which they share a common embryonic origin, hepatocytes
do not form secretory granules, which has cast doubts on their
suitability to function as insulin-secreting cells [17,18]. In work
previously performed on syngeneic murine primary hepatocytes
[19], we showed that high glucose concentration stimulated insulin
transcription from a bifunctional promoter in p3MTCHins,
consisting of the human metallothionein IIA promoter linked to
a carbohydrate response element [20], within 6–10 minutes and
secretion within 12 minutes. Basal insulin expression was restored
within 30 minutes of removing the glucose stimulus.
These results encouraged us to extend our approach to a large
animal model of diabetes in which we would attempt to modify
autologous hepatocytes for insulin secretion. While underlying
autoimmunity in type 1 diabetes leads to therapeutic failure after
islet or whole pancreas transplantation [21,22], insulin-secreting
hepatocytes are not targets for recurrent autoimmune destruction
[23]. If successful, this approach could be simpler than islet
transplantation, safer than hepatocyte transduction with viral
vectors and less empirical than transdifferentiating hepatocytes
into b-like cells. Moreover, primary adult hepatocytes would not
be expected to have the tumorigenic propensity of b-like cellular
implants derived from embryonic stem cells and modified cell lines
[24,25]. Other strategies being developed for cell-based correction
of metabolic deficiencies require reliable and efficient differenti-
ation of liver-derived cells or stem cells into the desired cellular
phenotype e.g. insulin or clotting factor production. However,
directed and trans-differentiation require several weeks of
manipulation and culture in vitro during which chromosomal
aberrations are known to develop [26,27]. We now describe ex
vivo electrotransfer of p3MTCHins into primary hepatocytes
freshly isolated from diabetic Yorkshire swine that were auto-
logously reimplanted directly into the liver parenchyma, under
visual or ultrasonic guidance, in a single 3-hour procedure. These
modified hepatocytes were effective insulin-secreting bioimplants
as evidenced by significant and durable correction of hyperglyce-
mia and other metabolic abnormalities associated with diabetes,
without evidence of tumor formation for at least 47 weeks. We also
showed by morphological studies and transcriptome analyses that
target organ injury secondary to poorly controlled diabetes was
substantially attenuated in treated swine.
Methods
Isolation of Primary Porcine Hepatocytes
A surgically excised liver wedge (50 cm
3) was sequentially
perfused (flow rate 8–10 ml/min) with 2.5 mM EGTA in calcium-
free Dulbecco’s phosphate buffer (8–10 min) and 0.3% (w/v)
collagenase IV-S (Sigma-Aldrich, U S A) (15–20 min) through two
catheters, each ligated to a visible vessel. Uncannulated vessels
were sutured. The perfused liver was diced and scraped to release
the cells. A cellular fraction enriched in viable hepatocytes was
obtained as a pellet after centrifugation (150 g, 15 min at 4uC) on
a discontinuous Percoll (GE Healthcare) gradient (15–30–45–
60%). Cell viability by trypan blue exclusion was 75–90%.
Gene Transfer
Isolated hepatocytes were electroporated using the Nucleofec-
tor
TM system (equal volume mixture of solutions #3551 and #3541;
program T20; Amaxa Biosystems, Koln, Germany) or with sterile
NC solution having the following composition: 19.8 mM KH2PO4/
80.2 mM K2HPO4/2 mM NaCl, pH 7.6. Freshly prepared 2 mM
ATP and 5 mM reduced L-glutathione were added to NC solution
just before use. Electroporation with NC solution was performed in a
sterile cuvette (4 mm gap; BTX Instrument Division, Harvard
Apparatus, U S A) with a single pulse of 1400 V, 70 ms followed
immediately by a single pulse of 160 V, 37 ms delivered from a
custom-madepulsegenerator.Eightmgendotoxin-freeplasmidDNA
(p3MTChins or pEGFP) was added to 4610
6 viable hepatocytes in
0.2 ml electroporation solution before electrical pulsing.
Induction of Insulin Expression In Vitro
Two610
6 hepatocytes were cultured on collagen I-coated
35 mm dishes in DMEM-25 mM glucose (supplemented with
10% fetal calf serum, penicillin 10,000 units/ml and streptomycin
10 mg/ml) in 5% CO2 at 37uC for at least 16 h. For static
induction, DMEM-25 mM glucose was replaced with DMEM
containing increasing concentrations of glucose alone or zinc
combined with either 2.5 mM or 25 mM glucose. Conditioned
media (24 h) of quadruplicate plates were assayed for human
insulin. To determine the time course of glucose-stimulated insulin
secretion, DMEM-25 mM glucose was replaced with DMEM-
2.5 mM glucose 3 h before commencing induction. Replicate
plates were then exposed to DMEM-25 mM glucose for 5–
90 min. The mean of 2 baseline time points i.e. 10 minutes and
immediately before cells were exposed to 25 mM glucose, was
taken as the unstimulated value. A parallel series of plates, after
exposure to DMEM-25 mM glucose for 90 min, was returned to
DMEM-2.5 mM glucose for 5–90 min during the de-induction
phase. At every time point during both induction and de-induction
phases, quadruplicate plates (replicate plates from each primary
hepatocyte preparations) were processed for human insulin assay
in the conditioned medium and total cellular RNA isolation
(RNeasy Fibrous Tissue kit, Qiagen, Germany).
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Tissues (kidney, retina, liver and aorta) harvested during
planned autopsies were flash frozen and homogenized with mortar
and pestle in liquid nitrogen. Total RNA extracted using the
guanidine thiocyanate method [28] was stored at 280uC.
RT-PCR
Semi-quantitative transcript analyses were performed as
described previously [19]. Primer sequences used were:
Human insulin (F: 59 ttt gtg aac caa cac ctg tgc;3 9;R :5 9 ggt tca agg gct
tta ttc cat ct 39), Human hypoxanthine phosphoribosyltransferase (F:
59gga tta cat caa agc act gaa tag 39;R :5 9ggc tta tat cca aca ctt cgt g 39), S.
scrofa insulin (F: 59ggc ctt cgt gaa cca gca c 39;R :5 9cca gct cca cgg cac ctg
39), S. scrofa glucagons (F: 59gtt tac cag tga cta cag c 39;R :5 9gtc tct caa
att cat cgt ga 39), S. scrofa somatostatin (F: 59gaa ctg gcc aag tac ttc 39;R :
59gct cca gcc tca ttt cat 39), S. scrofa pancreatic polypeptide (F: 59cct gcg
tgg ctc tgt tac tac 39;R :5 9ggt cag cat gtt gat gta tct ac 39), S. scrofa
hypoxanthine phosphoribosyltransferase I (F: 59gaa gag cta ctg taa tga
cca g 39;R :5 9gcc agt gtc aat tat atc ttc aac 39), Ampicillin resistance gene
(F: 59gca act tta tcc gcc tcc atc 39;R :5 9gca aac tat taa ctg gcg aac ta 39).
Hormone Radioimmunoassays
Porcine C-peptide (PCP), human insulin and C-peptide (HCP)
concentrations were quantified by radioimmunoassays (Linco
Research, U S A). We added 250 KIU aprotinin (Sigma-Aldrich)
to 1 ml whole blood intended for C-peptide assays. HCP assay had
no cross reactivity with PCP, human and porcine insulin. PCP
assay was ,1% cross-reactive with HCP and was not cross-
reactive with human and porcine insulin.
Animals
All animal handling procedures and animal husbandry were
conducted in an Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC)-accredited facility. The exper-
imental protocol was approved by the Institutional Animal Care and
Use Committee of the Singapore General Hospital. Male and female
Yorkshire pigs were fed standard chow twice daily (5% body weight).
Metabolic and Biochemical Tests
Capillary blood glucose was determined by ear prick and a
glucometer (Ascensia ELITEH, Bayer HealthCare, Germany). We
drew femoral venous blood periodically for measurements of
HCP, PCP and the following clinical serum and blood analytes:
fructosamine, urea, creatinine, electrolytes (potassium, sodium and
chloride), total protein and albumin, total bilirubin, alkaline
phosphatase, alanine aminotransferase (ALT), gamma-glutamyl-
transferase (GGT), triglycerides, total and HDL cholesterol.
Streptozotocin-Diabetic Swine
Pigs were fed ammonium chloride (1.5 g/kg body weight in 500 g
moistened chow)16 h beforea bolus earveininjection over 2 min of
streptozotocin (STZ; 150 mg/kg body weight; ZanosarH,P f i z e r )
followed immediately by 50 ml saline flushing [29]. Exogenous
insulin injections (LantusH, Sanofi Aventis; HumulinH R, Eli Lilly)
were administered to diabetic pigs only when fasting blood glucose
exceeded 11 mM during the 3-day period before surgery to reduce
the risk of post-operative sepsis. Insulin was not administered to any
animal at any time after hepatocyte implantation.
Intravenous Glucose Tolerance Test (IVGTT)
We performed IVGTT on 16 h overnight fasted animals. An
internal jugular vein was cannulated (7-French; Arrow Interna-
tional, Inc.) under general anesthesia. To establish the baseline, a
saline bolus (equal to the volume of glucose solution) was injected
over 3 minutes and blood was drawn 10, 20 and 30 min later for
blood glucose, plasma HCP and PCP assays. IVGTT was initiated
by a bolus glucose injection (1 g/kg; 25% w/v solution) over
3 minutes followed by 30 ml saline injection to flush the line.
Three ml of blood was drawn 1, 3, 5, 10, 20, 30, 45, 60 and
90 min after the glucose bolus for the same assays. To avoid
possible artifacts caused by hypovolemia, 3 ml heparinized saline
was injected after each blood sampling.
Surgical Procedures
(1) Resection of liver wedge. Fourteen diabetic pigs (9 male
and 5 female;17–23 kg) underwent excision of30%of the leftlateral
liver lobe (equivalent to ,10% of total liver mass) under general
anesthesia 10 days post-STZ administration. The left lateral liver
lobe was mobilized as previously described [30]. About 30% of the
lobe was resected en masse after applying a non-crushing clamp
across it. The main portal vein branch in the resected specimen was
immediately cannulated and perfused with cold calcium-free
Dulbecco’s phosphate buffer. Hemostasis was achieved with 5/0
Prolene sutures and diathermy. Surgicel (Johnson & Johnson, U S A)
was applied to the resected surface and the abdominal cavity was
washedwith5 mlofanantibioticsolution(penicillin100 mg/mland
ampicillin 100 mg/ml). The abdominal wound was closed with
continuous 2/0 Ethilon and the skin with 3/0 subcuticular Vicryl.
All surgical sutures were from Ethicon, U S A.
Primary hepatocytes prepared from excised liver tissue were
electroporated ex vivo with 2 mg p3MTChins DNA per 10
6 viable
hepatocytes and immediately reimplanted into the liver paren-
chyma using one of the methods below with comparable metabolic
outcomes.
(2) Hepatocyte implantation. Open method: The abdominal
cavity was left open after liver resection while hepatocyte isolation
and electroporation were performed. Transfected hepatocytes in
suspension were injected under direct vision inup to 5 sites of the left
and right central lobes with a 23G needle (3–4 ml/site).
Implantation sites were marked with a 5/0 Prolene suture. The
abdominal incision was then sutured close. Percutaneous method:T h e
abdominal incision was sutured immediately after liver resection.
The suspension of transfected hepatocytes was injected percuta-
neously into 3 sites in the left and right central liver lobes (5–6 ml/
site) using a SpinocanH spinal needle (22G, 3.5 inches long; B. Braun
Medical Inc., U S A) under real-time ultrasonic guidance (Acuson
XP10,USA).GelfoamHsuspension(1 ml)(Pharmacia&Upjohn,U
S A) was injected upon withdrawal of the needle from the liver
parenchyma for hemostasis. The number of hepatocytes implanted
using either method was 2.0–3.3610
8 in 15 ml DMEM.
The entire procedure from wedge excision to hepatocyte
implantation was completed in about 3 hours as a single surgical
operation.
Histology
Paraffin-embedded liver sections (4 mm) were immunostained
with the following primary antibodies according to manufacturers’
recommended protocols: ready diluted monoclonal mouse anti-
human insulin (Zymed Laboratories Inc., U S A), monoclonal
mouse anti-rat PCNA (1:50 dilution) and monoclonal rabbit anti-
human Ki-67 (1:100 dilution) (both from Acris Antibodies GmbH,
Germany). The latter two antibodies bind the corresponding
porcine antigens. Bound primary antibody was detected with
ChemMate
TM Envision
TM kit (Dako Cytomation, Denmark).
Sections were counterstained with hematoxylin (Sigma-Aldrich).
Standard histological evaluations were also performed on paraffin
Autologous Hepatocyte Implants
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(PAS) reagent, counterstained with hematoxylin.
Electron Microscopy
Scanning electron microscopy (SEM). Specimens were
fixed in 2.5% glutaraldehyde in phosphate-buffered saline for 24 h
at 4uC, then post-fixed in 1% OsO4, pH 7.4 for 2 h at room
temperature, followed by dehydration in a graded ethanol series
and drying in a critical point dryer. Preparations were coated with
gold for viewing (JSM-5660, JEOL, Japan). Transmission electron
microscopy (TEM) Specimens were fixed and post-fixed as for SEM.
After dehydration, specimens were embedded in epoxy resin
(polymerization at 60uC for 24 h). Ultra-thin sections (90–100 nm)
were stained with uranyl acetate and lead citrate and viewed in a
microscope (JEM-1220, JEOL, Japan) operated at 100 KV.
Basement membrane thickness was measured from TEM images
of 20 choroidal capillaries (10 measurements per capillary) and 20
renal glomeruli (10 measurements per glomerulus) using a
standard grid. The retina and kidney of three animals (healthy
control, untreated diabetic and treated diabetic pigs) were
compared. All measurements were made independently by three
individuals whose data were pooled for analysis.
Plasmid DNA Quantitation
Total DNA was extracted from paraffinized tissues (PuregeneH
DNA purification kit; Gentra Systems, U S A). A standard curve
was constructed from real-time PCR by spiking 50 ng pig liver
DNA with graded amounts of p3MTChins DNA (0, 1, 10, 50,
100, 500, 1,000, 5,000 and 10,000 pg). Primer sequences
amplified the ampicillin resistance gene unique to the plasmid.
Plasmid DNA detected in DNA of pig liver sections were
quantified from the standard curve-derived equation: log
DNA=20.2507 Ct+5.4122 (triplicate assays, r
2=0.9952).
Transcriptome Profiling
Study design. We transcriptionally profiled kidney, retina,
aorta and liver of normal healthy, treated diabetic and untreated
diabetic pigs (n=2 per group). All animals were matched for age,
sex and body weight. Treated diabetic and untreated diabetic
animals were autopsied 34–38 weeks and 36–42 weeks,
respectively, post-implantation. To ensure that the transcriptome
profiles were representative of the entire organs/tissues of interest,
we homogenized (i) a whole kidney; (ii) all retinal tissue of one eye;
(iii) equal segments from the aortic arch, thoracic and abdominal
aorta; and (iv) an equal portion from each liver lobe from every
pig. Ground tissues were mixed well before total RNA isolation.
Target preparation and hybridization. Biotinylated and
fragmented cRNA was prepared by the Affymetrix protocol and
hybridized to Affymetrix GeneChipH Porcine Genome Array
(each target organ from a single animal was profiled in duplicate;
there were thus 4 replicate transcriptome datasets for each organ/
tissue in each study group). Each array contained probe sets for
20,201 Sus scrofa genes and was scanned in a GeneChipH Scanner
3000 (Affymetrix Inc., Santa Clara, U S A).
Data analysis. We normalized signal intensities by global
scaling to an arbitrary value of 500 using Microarray Suite
software, version 5.0 (Affymetrix). We next analyzed normalized
data by target organ or tissue type. Genes with absent calls in $10
out of 12 datasets (2 arrays62 animals63 groups) were excluded.
We selected genes that were differentially expressed (i.e. $1.5-fold
difference) in three pairwise comparisons (i.e. normal vs. untreated
diabetic, normal vs. treated diabetic and treated diabetic vs.
untreated diabetic) using FiRe v. 2.2 [31]. These genes, listed by
log2 intensity values, were analyzed using Significance Analysis of
Microarrays (SAM) version 1.21 based on 1,000 permutations
[32]. Pairwise comparisons allowed us to obtain three gene sets,
each having a false discovery rate ,1%. The inter-relationship of
these three gene sets was established by Venn diagrams (FiRe v.
2.2 software).
Statistical Analysis
Data were expressed as mean6s.e.m. The number of animals is
denoted byN and the total number of data pointsbyn.Groups were
compared using Student’s unpaired two-sided t test (for data with
equal variances) or Mann-Whitney U-test (for data with unequal
variances). One-way ANOVA with Bonferroni correction was used
for multiple group comparisons. All statistical tests and the area
under the curve (AUC) were calculated with GraphPad Prism
(GraphPad Software Inc., U S A). Cluster analysis of GeneChipH
data was performed using algorithms in Genowiz (Ocimum
Biosolutions Ltd., India). P,0.05 was considered significant.
Results
Regulated Insulin Production In Vitro
The efficiency of electrogenetransfer in fresh porcine hepatocytes
was 40–50% using a proprietary nucleofection solution (Figure 1A).
We developed solution NC for electroporation and achieved
transfection efficiencies of .50% with .80% viability, and
consistently higher insulin secretion (Figure 1B). All experiments
thereafter used solution NC. The glucose- and zinc-responsive
promoter in p3MTChins was functional in porcine primary
hepatocytes. Insulin secretion by electroporated hepatocytes in vitro
was stimulated by glucose (4–25 mM) or zinc (5–20 mM) alone, with
highest induction by glucose and zinc combined (Figure 1C). These
glucose and zinc concentrations were within the physiological ranges
in pig blood, 3.4–15.3 mM (J. Laukkarinen, unpublished data) and
13–20 mM [33], respectively. Insulin secretion rate rose from 0.01 to
0.14 ng/10
3 hepatocytes/min (p,0.0001) from the 5th to 10th
minute after increasing glucose from 2.5 to 25 mM while in a
parallel incubation it remained stably low in 2.5 mM glucose
(Figure 1D). Insulin transcription increased 1.5-fold within 5 min in
25 mM glucose, and decreased by about 8-fold within 10 min of
restoring glucose concentration to 2.5 mM (Figure 1E).
Irreversible Ablation of Endogenous b Cells in
Streptozotocin-Diabetic Swine
Hyperglycemia developed within 48 hours of STZ administra-
tion and diabetes was stable for at least 49 wk. AUC20–90PCP (an
index of glucose-stimulated porcine insulin secretion) in the post-
STZ and late treatment phases were not significantly different
(p=0.6394), evidence that endogenous b cells did not regenerate
throughout the study (Figures 2A and 3F). Consistent with
selective b cell ablation in STZ-diabetic pigs, insulin mRNA by
RT-PCR was significantly decreased (p,0.0001; Figure 2B),
somatostatin and pancreatic polypeptide transcript levels were
unaltered, while glucagon mRNA showed the characteristic
increase associated with diabetes (p,0.0001) [34] (Figure 2B).
Pancreatic islets of diabetic swine did not stain for insulin unlike
normal pig pancreas (Figure 2C).
In Vivo Metabolic Effects After Implantation of Insulin-
Secreting Autologous Hepatocytes
Fourteen diabetic pigs were implanted with autologous
hepatocytes. In 10 pigs, hepatocytes were electroporated with
p3MTChins (treated group) while hepatocytes of the remaining 4
pigs were mock electroporated without plasmid (untreated group).
Autologous Hepatocyte Implants
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temporally sequential phases: pre-STZ (non-diabetic; $4 wk),
post-STZ (diabetic; 10 d), early and late treatment (#12 and 13–
47 wk, respectively, post-implantation). No animal received insulin
injections in the early or late treatment phases.
Glycemic correction. Mean fasting glycemia was significantly
lower in treated than in untreated pigs (p,0.0001) over the entire
study period of at least 47 wk (Figure 3A. See Table S1 for details of
Figure 3 and other biochemical data). Hypoglycemia (,2.8 mM)
was not recorded in .320 separate fasting and random blood
glucose measurements over this period. Glycemic profiles from
IVGTToftreatedanimalswererestoredalmosttotheirnon-diabetic
status(Figure 3B). IVGTTdatawere expressed asthe areaunder the
curve for blood glucose 20–90 min after intravenous glucose
(AUC20–90BG), an integrated measure of in vivo glucose utilization.
Among treated pigs, mean AUC20–90BG decreased 74% from pre-
implantation diabetic values, an effect that persisted into the late
treatment phase when it was comparable to AUC20–90BG of the non-
diabetic phase (p=0.1348) (Figure 3C).
Regulated insulin secretion in vivo. Improved glucose
tolerance was accompanied by near-normalization of the temporal
profile of serum transgenic HCP during IVGTT. It was noteworthy
that, similar to glucose-stimulated insulin secretion in vitro
(Figure 1D), serum HCP levels of treated pigs rose within 5 min
during IVGTT (Figure 3D), comparing favorably to the rise in
serum PCP within 1 min of the same animals before diabetes
induction (Figure 2A). Comparing IVGTT data of pre-STZ (serum
PCP) and post-implantation (serum HCP) phases, these
concentrations declined 40 min (0.0036 ng
21 ml
21 min
21)a n d
60 min (0.0020 ng
21 ml
21 min
21), respectively, after glucose
stimulation. IVGTT data of treated diabetic pigs showed that the
area under the curve for serum HCP 20–90 min after intravenous
glucose (AUC20–90HCP), an integrated measure of human insulin
secretionbyimplantedhepatocytes,was54%thatofAUC20–90PCP(a
comparable measure of endogenous insulin secretion from porcine
pancreatic islets) of the same animals before induction of diabetes.
Using species-specific C-peptide radioimmunoassays, glycemic
improvement was attributed to human insulin secreted from
transfected hepatocytes (Figure 3E) rather than recovery of
endogenous b cells as AUC20–90PCP values were not significantly
different between treated and untreated groups, and were
consistently ,16% of pre-STZ values (Figure 3F).
Metabolic correction. As pig erythrocytes are impermeable
to blood glucose [35], serum fructosamine was used instead as an
index of average glycemic control. Mean fructosamine
concentrations fell significantly from diabetic levels in treated
pigs (p=0.0014 early treatment; p,0.0001 late treatment). Unlike
untreated diabetic controls, serum fructosamine did not rise
significantly during the late treatment phase (p=0.1500 cf. early
treatment phase) (Figure 3G).
Emaciation is a known global metabolic effect of severe insulin
deficiency. Our data showed that clinically effective restoration of
insulin production was accompanied by a higher rate of body
weight gain in treated animals (p,0.0001 early treatment;
p=0.0002 late treatment cf. untreated controls) (Figure 3H).
Consistent with greater body weight gain, treated pigs had higher
late treatment phase serum creatinine levels compared to
untreated controls (p,0.0001) whose serum creatinine levels did
not change throughout all study phases (Figure 3I). There was,
however, no significant difference in blood urea and serum
Figure 1. Regulated insulin secretion by electroporated primary porcine hepatocytes ex vivo. (A) Electroporation using Amaxa
TM
solution transfected 40–50% hepatocytes with pEGFP. Merged brightfield and fluorescence images; original magnification 2006. (B) Human insulin
concentration in 24 h conditioned media of primary hepatocytes electroporated with p3MTChins (2 mg/10
6 cells) in Amaxa or NC solutions
(p=0.0026). (C) Human insulin concentration in 24 h conditioned media of p3MTChins-electroporated hepatocytes. Thresholds for stimulating insulin
secretion were 4 mM glucose (p=0.0018 cf. 2.5 mM glucose) and 5 mM zinc (p,0.0001 cf. no zinc). Data are means6s.e.m. of quadruplicate
experiments. (D) Time course of insulin secretion by electroporated hepatocytes. Insulin secretion increased from 0.01 to 0.14 ng/10
3 hepatocytes/
min (p,0.0001) after 5 min in 25 mM glucose but not in 2.5 mM glucose over 85 min. Data are means6s.e.m of quadruplicate experiments from 2
primary hepatocyte preparations. (E) Insulin mRNA, quantified by real time RT-PCR after subtracting a parallel minus-RT control and normalising to
HPRT1 mRNA [19], rose within 5 min in 25 mM glucose (p,0.0001) and fell within 10 min in 2.5 mM glucose (p=0.0149). Values are mean6s.e.m. of
triplicate experiments.
doi:10.1371/journal.pone.0001734.g001
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higher serum creatinine levels were the result of increased muscle
mass in treated animals rather than impaired renal function [36].
Dyslipidemia secondary to diabetes was also corrected. Among
treated pigs, mean total serum cholesterol concentration was
significantly reduced in the early treatment phase (p=0.0035 cf.
diabetic levels) while it remained unchanged in untreated animals
(p=0.9793) (Figure 3J). Hypertriglyceridemia developed acutely
after induction of diabetes in both groups and significantly improved
only in treated pigs during the early treatment phase (p,0.0001)
(Figure 3K) and was not significantly different from the pre-STZ
phase (p=0.4935). However, serum cholesterol and triglyceride
concentrationsof untreated diabetic pigs also fellsubstantially during
the late treatment phase (Figure 3J and 3K)–even to levels below
their own non-diabetic values. This hypolipidemia associated with
severe diabetes was a known effect of prolonged starvation and
weight loss on lipoprotein metabolism [37].
High serum ALT activities are typical of liver dysfunction in
poorly controlled diabetes and readily reverse after correction of
hyperglycemia [38]. Mean serum ALT activities of treated animals
during pre-STZ and late treatment phases were not significantly
different (p=0.8508) showing that treatment had effectively
prevented diabetes-related liver dysfunction. In contrast, serum
ALT activity rose progressively in untreated controls and were
higher during the late treatment phase compared to both the early
treatment and pre-STZ phases (p=0.0086 and ,0.0001, respec-
tively) (Figure 3L).
Treatment outcomes correlated with number of
hepatocytes implanted. Correction of disordered glucose
metabolism by several objective measures-fasting glycemia
(Figure 3M), intravenous glucose tolerance (Figure 3N) and
serum fructosamine levels (Figure 3O)–was the result of restored
insulin production shown by fasting serum HCP levels (Figure 3P)
and AUC20–90HCP (Figure 3Q). All these outcome measures
correlated significantly with the number of hepatocytes implanted.
In contrast, cell number did not correlate with serum total
bilirubin concentrations (Figure 3R) or serum GGT activity
(Figure 3S) showing that direct intrahepatic placement of
hepatocytes, suspended in up to 15 ml, did not cause cholestasis.
Overall restoration of normal liver functions in treated animals
could be inferred from serum albumin trends. Serum albumin
concentrations were positively and significantly correlated with the
number of hepatocytes implanted (Figure 3T). They were also
significantly lower in the late treatment phase of untreated animals
compared to pre-STZ values (p,0.0001). In contrast, serum
albumin concentrations in the late treatment phase of treated
animals were not significantly different from the corresponding
pre-STZ values (p=0.1995).
Engraftment of Insulin-Secreting Hepatocytes
Despite clear evidence of continuing transgenic insulin expression
and metabolic correction in the treated animals, autopsies were
performed on healthy controls, untreated diabetic and treated
diabetic pigs 34–47 weeks post-implantation to systematically
evaluate engraftment, vector persistence and target organ injury.
Autologous insulin-secreting hepatocytes had engrafted mainly,
but not only, around portal triads and central veins (Figure 4A–C).
Therewerenofeaturesofdisorderedlobulararchitectureorcirrhosis
in the implanted livers. No tumors were detected during careful
examination of the liver, spleen, intestinal tract, peritoneal cavity,
kidneys, adrenals, lungs and heart. Fasting serum HCP levels during
the first week after implantation (0.4460.03 ng/ml) stabilized at
0.3160.02 ng/ml after 4 weeks, consistent with functional engraft-
ment of 70% of implanted hepatocytes. Concordant with persistent
secretion of transgenic insulin (Figure 3E), plasmid DNA was
detected 3 and 8 months post-implantation using vector-specific
primers for PCR of total DNA extracted from thick sections of liver
that showed insulin-producing hepatocytes (Figure 4D). In contrast,
vector DNA was barely detectable in the same liver lobes distant
from implantation sites.
Physiological concentrations of insulin are mitogenic [39] and
liver tumors have been reported in all diabetic animals
intrahepatically transplanted with low numbers of pancreatic islets
[40]. However we showed that, compared to liver from a healthy
control, the liver of implanted animals did not show increased
mitogenic activity as assessed by immunostaining for proliferating
Figure 2. Absence of insulin expression in pancreatic b cells of STZ-diabetic pigs. (A) Persistent abolition of IVGTT-induced rise in serum
PCP in the late treatment phase (13–47 wk after hepatocyte transplantation). Data are from 14 pigs. (B) Transcript analyses of islet hormones from
pancreata of healthy, untreated diabetic (38–46 wk post-STZ) and treated diabetic (38–49 wk post-STZ) pigs (n=2 per group) by real time RT-PCR as
in Fig. 1E. Insulin mRNA was significantly decreased and glucagon mRNA significantly increased in both groups of diabetic pigs compared to healthy
controls (p,0.0001 for all comparisons). Both diabetic groups had similar expression of insulin and glucagon (p=0.4041 and 0.2308, respectively).
Somatostatin and pancreatic polypeptide expression was not significantly different among all groups. (C) Insulin-positive cells in normal islets of a
healthy pig cf. absent in diabetic pigs 38 wk post STZ.
doi:10.1371/journal.pone.0001734.g002
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PLoS ONE | www.plosone.org 6 March 2008 | Volume 3 | Issue 3 | e1734Figure 3. Glycemic and metabolic correction after implantation of insulin-secreting autologous hepatocytes. Aggregated data are
presented from four sequential phases: pre-STZ (non-diabetic phase); post-STZ (#10 d after STZ injection); early treatment (#12 wk post-
implantation) and late treatment (13–47 wk post-implantation) for 10 treated and 4 untreated pigs. See Supporting Table S1 for number of animals
(N), separate analyses (n), means, s.e.m. and range for all biochemical tests performed. (A) Mean fasting glycemia in early and late treatment phases
were significantly lower in treated pigs (p,0.0001 for both phases). (B) Glycemic profiles during IVGTT in the 4 study phases. Pre- and post-STZ
profiles are pooled data from all pigs. Profiles of treated and untreated pigs were from the late treatment phase. (C) Glycemic data from panel (B)
expressed as AUC20–90BG. Implanted insulin-secreting hepatocytes improved glucose tolerance (*, p,0.0001) with durable effect (p=0.3481 early vs
late treatment phase). (D) Serum HCP levels in treated pigs increased 5 min after intravenous glucose (p=0.0124 and 0.0633 in the early and late
treatment phases, respectively, cf. unstimulated HCP levels). (E) AUC20–90HCP of treated pigs was comparable in both treatment phases (p=0.8279). (F)
AUC20–90PCP confirmed b-cell ablation in STZ-diabetic pigs throughout the study (p,0.0001 both treatment phases cf. pre-STZ phase); *, p=0.8279.
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PCNA and Ki67 staining was observed in both insulin-secreting as
well as adjacent hepatocytes, indicating that ectopic insulin
secretion in the liver did not have autocrine or paracrine
mitogenic effects. Insulin-secreting hepatocytes were morpholog-
ically normal without features of cellular transformation.
Treatment Attenuated Target Organ Injury
Tissues obtained from systematic autopsies performed on sex- and
age-matched normal healthy Yorkshire pigs, untreated diabetic and
treated diabetic pigs (2 animals per group) were evaluated to
ascertain effects of treatment on diabetes-induced target organ
injury. To allow sufficient time for development of secondary micro-
and macrovascular complications, both groups of diabetic animals
were maintained for 34–42 weeks before autopsy.
Treatment effects on tissue structure. Both untreated
diabetic pigs had dense posterior subcapsular cataracts but not
both treated pigs (Figure 5A). The choroidal capillary basement
membrane in the retinae of untreated diabetic pigs was thicker
than that of both healthy and treated diabetic animals (Figure 5H;
p,0.0001 for both comparisons). In contrast, there was no
difference between capillaries of healthy and treated diabetic
animals (p=0.8260). Another striking feature of choroidal
capillaries in untreated diabetes was the presence of an
additional cell layer invested with its own basement membrane
(Figure 5C). Retinal capillary permeability was normal by
fluorescein angiography (Figure 5B).
Kidneys of untreated diabetic pigs showed mesangial hyperpla-
sia and arteriolar thickening, characteristics of diabetic nephrop-
athy that were absent in healthy and treated diabetic animals
(Figure 5D). Glomerular basement membranes were thicker in
untreated diabetic pigs compared to healthy (p=0.0002) and
treated diabetic pigs (p=0.0007) (Figures 5E and G). Notably,
glomerular basement membrane thickness of treated diabetic pigs
was not different from healthy controls (p=0.9023).
Scanning electron microscopy of carotid arteries from an
untreated diabetic pig showed a smoothened endothelial surface,
abnormal microvilli and clumped erythrocytes with fibrin
adhering to the endothelium while carotid arteries of a treated
diabetic pig appeared more similar to a healthy animal (Figure 5F).
Hepatocytes of untreated diabetic pigs stained more intensely
with periodic acid-Schiff stain (Figure 5G) indicative of glycogenic
hepatopathy, a known but less well-recognized complication of
diabetes [38].
Treatment effects on target organ transcriptomes. Tran-
scriptional changes are sensitive molecular sentinels of the injurious
effects of diabetes on organs targeted for developing secondary
complications [41] e.g. renal failure, blindness and vascular
insufficiency. Retina, kidney, aorta and liver of healthy normal
pigs, untreated diabetic and treated diabetic pigs were flash frozen in
liquid nitrogen and transcriptionally profiled because these organs
are known targets for the microvascular, macrovascular and
metabolic complications of diabetes. We compared each tissue
transcriptome among the three animal groups. Of 20,201 genes
representedonthemicroarray,subsetsof625,233,419and69genes
were identified as diabetes-associated in aorta, kidney, liver and
retina, respectively, using two filters of significance (Figure 6A).
Among the most highly dysregulated diabetes-associated genes were
protein kinase C and vascular cell adhesion molecule in aorta,
retinol-binding protein and angiopoietin-like protein in kidney,
lipoprotein lipase and apolipoprotein A-IV in liver, vasoactive
intestinal peptide receptor and serpin peptidase inhibitor in retina.
Implantation of insulin-secreting autologous hepatocytes in diabetic
pigs corrected dysregulated expression of 58% (363 of 625), 38% (89
of 233), 48% (203 of 419) and 54% (37 of 69) genes in aorta, kidney,
liver and retina, respectively (Figure 6B). Unsupervised clustering of
diabetes-associated genes in each tissue transcriptome showed that
treated diabetic pigs generally clustered with healthy controls than
with untreated diabetic pigs (Figure 6C).
Discussion
This study demonstrates that autologous primary adult hepato-
cytes ofa large preclinical animal can be efficiently, simply andsafely
electroporated ex vivo with a nonviral vector to physiologically
express, process and secrete insulin in vivo with substantial
therapeutic efficacy for at least 47 weeks. Furthermore, we provide
evidence that such treatment attenuated tissue injury secondary to
diabetes i.e. metabolic, micro- and macrovascular complications. In
addition, our data indicate a ‘dosing effect’ i.e. glycemic correction,
glucose tolerance and human C-peptide secretion were each
correlated significantly with the number of implanted hepatocytes.
Our data showing that significant metabolic correction was achieved
by transfected hepatocytes whose glucose-stimulated insulin secre-
tion exceeded 50% that of endogenous b cells is in agreement with
maintenance of normoglycemia in human subjects after 50%
pancreatectomy [42]. The number of autologous hepatocytes we
implanted was about 10-fold lower than the number of allogeneic
donor hepatocytes that partially corrected inherited factor VII
deficiency in two children [43].
Use of a porcine model that resembles humans in size, anatomy,
physiology and pathophysiology has moved our approach closer to
clinical application. Despite many past attempts at developing
gene- and autologous cell-based diabetes treatments, none of the
approaches that are effective in murine diabetes has been
successfully adapted to large animals, let alone human subjects.
r
(G) Mean serum fructosamine levels were lower in treated pigs in the early and late treatment phases (p=0.0014 and ,0.0001, respectively. cf.
untreated pigs). Fructosamine levels did not rise significantly in treated pigs (p=0.1500) but did increase among untreated pigs (p=0.0015; early vs
late treatment phase). (H) Body weight gain was higher among treated pigs (p,0.0001 early treatment and p=0.0002 late treatment phase). (I) Mean
serum creatinine concentration in treated pigs during the late treatment phase was significantly higher than untreated diabetics (p,0.0001). (J) Total
serum cholesterol was higher in untreated pigs during the early treatment phase (p=0.0035). Treated pigs maintained normocholesterolemia during
the late treatment phase. Reduced serum cholesterol levels in untreated pigs during the late treatment phase were associated with marked weight
loss. (K) Hypertriglyceridemia developed acutely in all pigs after onset of diabetes (p=0.0002). It declined significantly in treated pigs during the early
phase (p,0.0001 cf. untreated pigs). Marked reduction in serum triglyceride concentrations during the late treatment phase was associated with
severe weight loss in untreated pigs. (L) Mean serum ALT activities in treated pigs during pre-STZ and late treatment phases were comparable
(p=0.8508) but were significantly higher in untreated pigs (p,0.0001 pre-STZ vs both treatment phases). Serum ALT decreased in treated pigs (early
vs. late treatment values, p=0.0228) but rose significantly in untreated pigs over the same period (p=0.0086). (M–Q) The number of transplanted
hepatocytes correlated with percentage decrease in fasting hyperglycemia, decrease in AUC20–90BG, stabilization of serum fructosamine, rise in fasting
serum HCP levels and AUC20–90HCP. (R, S) Serum bilirubin and c-glutamyl transpeptidase levels did not correlate significantly with the number of
implanted hepatocytes but (T) serum albumin levels correlated positively.
doi:10.1371/journal.pone.0001734.g003
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among others that continue to impede clinical development of
genetic and cellular therapies [18,44]. Allogeneic whole pancreas
and isolated islet transplantation have a proven record of success
in well-selected diabetic patients [21,22,45]. It is evident, however,
that these procedures have a restricted impact in diabetes care
because of donor scarcity, specialised skills required and high
treatment costs. By using autologous hepatocytes, our approach is
not donor dependent, technically facile and does not require long-
term immunosuppression. Rodent studies suggest that insulin-
expressing hepatocytes may be protected from the anti-beta cell
specific immune response underlying autoimmune diabetes [23].
In this study, we chose to isolate hepatocytes from surgically
accessible autologous liver that was capable of yielding hepatocytes
in adequate number and quality in a planned procedure. The
amount of excised tissue (less than 10% of the liver) was well within
the regenerative capacity of the liver to restore [47]. We chose to
reimplant hepatocytes directly into the liver parenchyma instead of
via the portal vein, as practised by most investigators, because more
than 70% of portal vein-infused hepatocytes were trapped within the
liver vasculature and quickly destroyed by blood macrophages,
leaving only a small fraction to engraft successfully [48] while up to
50% were distributed to extrahepatic organs [49]. Portal infusion of
hepatocytes in adult pigs was associated with intraportal thrombosis
and pulmonary embolism with infarction [50]. In contrast,
hepatocytes implanted directly into the liver parenchyma did not
distribute to other organs and integrated normally into liver lobules
[51]. Here we show that intraparenchymal hepatocyte implantation
achieved significant engraftment, did not disrupt normal hepatic
lobulararchitecture, did not alter normal biochemicalindices ofliver
function, was safely performed percutaneously under ultrasonic
guidance with comparable results to open implantation and thus was
not inferior to portal venous infusion of cells. A single surgical death
from intraabdominal hemorrhage due to iatrogenic liver laceration
occurred during percutaneous implantation. This animal was
excluded from analysis. There was no surgical mortality and
morbidity after we adopted the reverse Trendelenburg position for
percutaneous hepatocyte implantation.
We chose to test the feasibility of this approach in a pre-clinical
diabetes model for several reasons. Deficiency of a single circulating
protein i.e. insulin underlies type 1 diabetes and is a significant
abnormality in the later stages of type 2 diabetes. Despite multiple
treatment methods, a lifetime of euglycemic control is achievable
only with intensive efforts that are difficult to sustain. Hepatocytes
are suitable candidates for developing insulin-secreting bioimplants
because of their proven physiological glucose-sensing and glucose-
responsive characteristics, and proficiency in protein biosynthesis
and secretion. Portal venous drainage makes the liver a prime
anatomic location for nutrient-regulated insulin secretion. Although
hepatocytes lack secretory granules, we showed dynamic changes in
insulin secretion in tandem with changes in extracellular glucose
concentrationsthat weresufficientlyrapidtobenear-physiological in
onset and offset. Consequently, hypoglycemia was not recorded or
clinically observed even after 16-hour fasts. This is noteworthy as
current clinical practice aimed at achieving tight glycemic control
often increases the risk of hypoglycemia. For instance, diabetic
children on conventional insulin therapy sustain about 20 hypogly-
cemic comas and convulsions per 100 patient years [52].
Therapeutic efficacy in this study extended beyond glycemic
and metabolic (including dyslipidemia) correction to protection
against complications secondary to tissue injury. Our data provide
evidence that early and effective restoration of normal metabolism
in diabetes prevents microvascular and macrovascular abnormal-
ities in the eye, kidney and large vessels [53], as well as diabetic
hepatopathy [38]. Basement membrane thickening was more
severe in choroidal capillaries than in renal glomeruli probably
Figure 4. Engraftment of insulin-expressing autologous hepatocytes. Immunostained liver 36 wk after hepatocyte transplantation showed
normal lobular architecture and insulin-producing hepatocytes engrafted around the portal triads (A) and central veins (B). Panels (B) and (C) show
co-staining for insulin and mitotic markers, PCNA and Ki67, respectively. Mitotically positive cells were rare (arrowed). (D) Quantitative PCR using
vector-specific primers detected p3MTChins in liver 3 and 8 mo after implantation. The amount of vector detected in each sample is expressed in ng
plasmid DNA below the panel.
doi:10.1371/journal.pone.0001734.g004
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PLoS ONE | www.plosone.org 9 March 2008 | Volume 3 | Issue 3 | e1734Figure 5. Treatment attenuated target organ injury. (A) Example of a dense cataract observed only in untreated diabetic pigs. (B) Retinal
fluorescein angiography showed normal capillary permeability. (C) TEM of retina showed thickened basement membrane of a choroidal capillary,
duplicated basement membrane (red arrow) and an extra layer of cells in the capillary wall (blue arrow). (D) H&E stained kidney sections showed
enlarged glomeruli with mesangial expansion, and arteriolar wall thickening (arrow) in untreated diabetes. (E) TEM of untreated diabetic kidney
showed thickening of glomerular basement membrane. (F) SEM showed abnormal endothelial surface structures only in carotid arteries of untreated
diabetic pigs. (G) Increased intensity of PAS staining in untreated diabetic liver without fibrosis or cirrhosis. (H) Basement membrane thickness,
measured in 20 choroidal capillaries and 20 renal glomeruli of each group (n=2), was significantly greater in untreated diabetes cf. both treated and
healthy animals. *, treated vs. untreated.
doi:10.1371/journal.pone.0001734.g005
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[54], and suggests that ocular tissue injury from ischemia is a likely
early complication of poorly controlled diabetes. These findings
advocate more aggressive clinical management to attain and
maintain normoglycemia early in the course of diabetes as effective
protection against serious target organ injury.
Other salient features of our approach contributed to the
outcome of this study. Because we chose to use non-tumorigenic
primary and autologous cells that are resistant to most conven-
tional techniques of gene transfer, we resorted to an ex vivo
approach using electrical pulsing conditions that would cause
severe tissue necrosis, if administered in vivo. Avoiding primary
cultures was possible because we did not aim to transdifferentiate
hepatocytes into b-like cells and our electroporation technique
achieved high transfection efficicencies (.50% with .80%
viability). This also obviated the risk of inducing adverse genomic
instability knownto occurwhenprimarysomatic cellsare culturedin
vitro [26,27]. Ex vivo electroporation of primary hepatocytes with
nonviral vectors is likely to be more clinically acceptable than viral
transduction for its comparable efficiency and simplicity [55]. Ex
vivotransductionofprimaryhepatocyteshastheattendantriskofco-
implanting free viral particles with attendant risks of adverse
immunogenic or genotoxic effects. Compared to viral vectors,
pharmaceutical grade plasmid vectors are simpler and less costly to
produce, have low toxicity and immunogenicity, and are non-
pathogenic. Histological examination shows that plasmid-electropo-
rated hepatocytes were morphologically normal without features of
cellular transformation. This showed that electroporation of
hepatocytes with a nonviral vector was safe i.e. was not oncogenic
or mutagenic. Indeed, mutations resulting from rare plasmid
integrations after electroporation are estimated to be at least three
orders of magnitude lower than the background frequency of
spontaneous genome mutations [56]. Although short-termtransgene
expression is generally expected from non-integrating vectors,
several reasons explain the surprisingly sustained therapeutic effects
we achieved namely, physiological mammalian promoters, unlike
viral promoters, are less susceptible to silencing [57], electroporation
transfers vectors in high copy number [58] and non-mitotic
hepatocytes durably retain plasmid vectors [55].
We recognize that our approach could have greater clinical
appeal if the method for procuring autologous primary hepato-
cytes were less invasive. In this regard, it may be possible to
employ laparoscopic resection of an even smaller liver wedge
(currently about 10% of total liver mass) in future. This adaptation
will require hepatocyte isolation in higher yield and greater
transfection efficiency without compromising cell viability.
In conclusion, our approach simultaneously addresses several
major difficulties in the field of cellular therapy i.e. donor scarcity,
Figure 6. Transcriptional profiling of aorta, kidney, liver and retina. (A) Venn diagram of genes whose expression was significantly different
in pairwise comparisons: N vs U; N vs. T and T vs. U (N, healthy controls; T, treated diabetic; U, untreated diabetic pigs. n=2 per group). Genes $1.5-
fold different in expression in pairwise comparisons were analysed by SAM (significance analysis of microarray) based on 1,000 permutations (false
discovery rate ,1%). Shaded areas denote diabetes-affected genes. (B) Expression of diabetes-affected genes in untreated and treated pigs grouped
in increasing order of differential expression relative to healthy pigs. Genes represented by multiple probe sets were merged and averaged. (C)
Unsupervised hierarchical clustering of diabetes-affected genes showed a distinct tendency for tissue transcriptomes of treated diabetic and healthy
pigs to cluster together. Replicate transcriptional profiles of the same animal are designated 1 and 2, or 3 and 4 (i.e. 2 pairs of transcription datasets
per group of 2 animals). Numbers on selected nodes of each dendrogram are the dissimilarity index (D.I.).
doi:10.1371/journal.pone.0001734.g006
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immunosuppression, tumorigenicity of cell implants derived and
differentiated from embryonic stem cells, immuno- and genotoxicity
ofviral vectors as wellas transienttransgene expression. Moreover, it
warrants consideration for clinical development beyond diabetes
because it has broad potential application for treating other acquired
and inherited diseases for which systemic reconstitution of a specific
protein deficiency is critical and could be especially facile for diseases
that do not demand tightly regulated transgene expression.
Supporting Information
Table S1 Biochemical data
Found at: doi:10.1371/journal.pone.0001734.s001 (0.11 MB PDF)
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